Clinical Trial

RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 9, 2024 (before its estimated July 6, 2026 completion). Its status may not reflect the trial's current state.
Summary
A single-arm, single-center phase II trial study to assess the efficacy and safety of disitamab vedotin plus cadonilimab as first-line therapy for HER2-overexpressing advanced stomach carcinoma
Trial Details
NCT Number NCT06492317
Lead Sponsor The First Affiliated Hospital of Zhengzhou University
Conditions HER2-positive Gastric Cancer
Enrollment 20 participants
Start Date 2024-07-06
Primary Completion 2026-07-06 (estimated)
Study Completion 2027-07-06 (estimated)
Updated on ClinicalTrials.gov 2024-07-09